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Abstract
Background: Mucopolysaccharidosis type I is an autosomal recessive disorder caused by deficiency of α-L-iduronidase
and characterized by a progressive course with multisystem involvement. Clinically, Mucopolysaccharidosis type I is
classified into two forms: severe (Hurler syndrome), which presents in infancy and is characterized by rapid progressive
neurological involvement and attenuated (Hurler/Scheie and Scheie syndromes), which presents with slower progression
and absent to mild nervous system involvement. The specific treatment for attenuated Mucopolysaccharidosis
type I consists of enzyme-replacement therapy with laronidase (human recombinant α-L-iduronidase,
Aldurazyme). We present here the clinical and laboratory results in an 12-year-old patient affected by the
attenuated form of Mucopolysaccharidosis type I treated by enzyme-replacement therapy from the age of
5 months, compared with his 17 year old affected sister, who started therapy at 5 years of age.
Case Presentation: Clinical evaluation of these siblings shows that initiation of therapy prior of the onset of
clinically detectable disease resulted in considerable improvement in outcome in the young sibling. After
12 years of enzyme-replacement therapy, facial appearance, linear growth rate, and liver and spleen volumes
were normal; moreover, the degree of joint disease, vertebral, and cardiac valvular involvement were only
minimal compared with those of his sister.
Conclusion: This study demonstrates that early diagnosis and early initiation of enzyme-replacement therapy
substantially modify the natural history of the attenuated form of Mucopolysaccharidosis type I.
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Background
Mucopolysaccharidosis type I (MPS I) is an autosomal
recessive disorder caused by the deficiency of α-L-
iduronidase and characterized by a progressive multisys-
tem disease with ophthalmologic, cardiac, gastrointestinal,
pulmonary, skeletal and nervous system involvement.
Although there is considerable clinical heterogeneity,
patients fit into two broad clinical phenotypes: severe, also
known as Hurler syndrome, and attenuated, previously
termed Hurler/Scheie and Scheie syndromes [1]. Hurler
syndrome presents in early infancy and is characterized
by early and progressive multisystem disease including
neurological involvement and, when untreated, leads to
death within the first decade of life. Attenuated MPS I
patients show considerable clinical heterogeneity, with
symptom presentation most commonly in the mid to
late childhood, but definitive diagnosis can be delayed into
the second decade. Patients with attenuated disease show
slower but relentless multisystem disease progression with
absent to mild primary central nervous system involve-
ment. Life expectancy for untreated attenuated MPS I
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patients ranges from the second decade to normal life
expectancy.
Enzyme replacement therapy (ERT) with laronidase,
recombinant human α-L-iduronidase (Aldurazyme) has
become the standard of care for attenuated MPS I
patients [2]. We present here a 12 year follow up of a
previously reported patient with attenuated MPS I [3]
who started ERT at the age of 5 months, in comparison
with his older sister who started the therapy at 5 years
of age. To our knowledge, there are no other patients
treated before 6 months of life and followed for this
extended period of 12 years.
Case presentation
Siblings
This brother and sister pair are currently 12 years, and
17 years of age, respectively. The sister was diagnosed with
MPS I at the age of 5 at which time she had classic
features of attenuated MPS I. The diagnosis in the sister
led to the diagnosis in the brother shortly after birth. Full
case details can be found in the previous publication [3].
Both siblings are compound heterozygotes for the IDUA
mutations W402X and L535F. Complete clinical and
biochemical evaluations have been performed annually on
both children. Each commenced weekly laronidase infu-
sions at a dose of 0.5 mg/kg at the ages of 5 months
(brother) and 5 years (sister). Infusions took place in hos-
pital with the use of implanted venous access devices; they
were well tolerated with no reported reactions and in
addition very few infusions were missed.
Sibling 1
Patient M (male) (Fig. 1); weight is 56.0 Kg (>97th
percentile), height 168.0 cm (>97th percentile), HC
57.2 cm (98th percentile). Since the age of 2, this child
has been in the 97th percentile for height. Parental
heights: father 170.0 cm (20th percentile) mother
165.0 cm (75th percentile).
At the age of 12 years this boy has not developed
characteristic facial features of MPS I. He is intellectually
normal (IQ: 116) with a quality of life (assessed by EQ-
5D-Y) [4] of 100/100; no respiratory or sleep disturbances
are reported; no hepato-splenomegaly at clinical examin-
ation. Musculoskeletal evaluation reveals evidence of mild
limitation of flexion-extension of wrist (60/30; n.v. 75/70),
ankle and of the 4th and 5th fingers bilaterally; shoulder
and hip range of motion are normal and there is no
evidence of scoliosis. Formal hearing assessment is nor-
mal, ophthalmologic evaluations have shown mild corneal
clouding, first noted at 12 months of the age that has
remained unchanged. From the age of 7 years he has
developed mild hyperopia and astigmatism that is com-
pletely corrected by lenses. Echocardiographic evaluations
demonstrated evidence of mitral and tricuspid valve
thickening with mild insufficiencies, first detected at the
age of 7 years; mild atrial dilatation was detected by age 9,
but remains substantially unmodified to date (NYHA
classification: I). Skeletal X-rays at age 10 showed evidence
of minimal dysostosis multiplex of lower thoracic verte-
bral bodies (Fig. 2a) and triangular shape of some cervical
bodies (Fig. 2b); hand X-rays were normal (Fig. 2c) and
substantially unchanged. Bone densitometry is normal.
Electroneurography shows bilaterally mild signs of median
nerve suffering. Brain MRI is normal. No recurrent
infections are reported. ABR and audiometry are within
normal values.
Total urinary glycosaminoglycan (GAG) excretion were
elevated before ERT and normalized after 4 months of
therapy [3]. GAG determination on samples taken just
before infusion remained within age related normal ranges
until 8.5 years of age; at this time the levels increased to
89 μg/cr (nv: 37 μg/cr ± 18) by the age of 10.5 years, and
subsequently normalized. Urinary GAG elecrophoresis,
characterized before ERT by the presence of dermatan
sulphate (DS) and heparan sulphate (HS), normalized after
4 months of ERT up to the age of 6 years, when the
presence of DS and chondroitin sulphate (CS) with a ratio
of 50/50 was observed up to date.
Fig. 1 Patient M at the age of 10 years and Patient F at the age
of 14.5 years
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Plasma GAG determination at the age of 11.5 years
was 2.8 μg/ml (nv: 2.7 μg/ml ± 1.12), with a CS/DS ratio
of 98/2 (nv: 100/0); these are similar to levels obtained
at the age of 6, 9 and 10 years. No pre ERT plasma
sample was available. After 12 years of ERT circulating
anti-laronidase antibodies were not detectable by ELISA
methodology.
Sibling 2
Patient F (female) (Fig. 1) weight is 58.0 kg (>50th
percentile), height 154.0 cm (10th percentile), and HC
59 cm (>97th percentile). She is intellectually normal
(IQ: 80), with a quality of life (EQ-5D-Y) of 100/100;
menarche began at the age of 12 years with a normal
pubertal growth spurt. After 12 years of ERT she still has
Fig. 2 Patient M at the age of 11 years: (a) mild ovoid shape of low vertebral bodies; (b) mild triangular shape of cervical bodies; (c) no signs of
multiplex dysostosis of the hands
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moderate facial coarseness (Fig. 1). Liver and spleen vol-
umes normalized within the first year of ERT and have
remained within normal limits at clinical examination.
Musculoskeletal evaluation shows progression of joint
disease with limitation of range of motion of both prox-
imal and distal joints. She has developed contractures of
all of her digits (claw hand deformity) and severe restric-
tion of range of motion of all joints; in particular elbows,
knees and ankles showed fixed flection to 15, 20 and 15°,
respectively; the spine is straight. She cannot completely
raise her arms above the head. Ophthalmologic evalu-
ation reveals diffuse and prominent corneal clouding
present since the age of diagnosis; the degree of cloud-
ing has remained unchanged after 12 years of therapy.
At the age of 11 years she developed hyperopia and
astigmatism, completely corrected by lenses (visual
acuity: 10/10). She has had persistent recurrent otitis
media and has mild bilateral conductive hearing loss
persistent at the age of 16 years, confirmed by ABR and
audiometry. No respiratory or sleep disturbances are
Fig. 3 Patient F at the age of 16 years: multiplex dysostosis signs at thoracic (a) and cervical (b) bodies and hands (c)
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reported. Cardiac evaluations demonstrated no signifi-
cant progression of previously reported moderate mi-
tral insufficiency with thickened valve leaflets, anterior
edge prolapse and mild left atrium thickening (NYHA
classification: II). Skeletal X-rays show no improvement
of her moderately severe dysostosis multiplex with evi-
dence of slight worsening of thoracic vertebral changes
but stable cervical and hand findings (Fig. 3a, b and c).
Signs of multiplex dysostosis were already present in
the girl at the age of 4 years and 6 months [3]. Bone
densitometry is normal for age. Spirometry yielded a
mixed ventilator pattern (FVC 66 %, FEV1 70 %, PEF
71 %, FEF25–75 79 %); inspection of the flow-volume
curve revealed abnormal flattening of the expiratory
loop, which was suggestive of variable airway obstruc-
tion. Cerebral MRI shows no white matter alterations;
electroneurography shows bilaterally mild signs of me-
dian nerve compression. Due to a progressive walking
difficulty at the age of 16 years, a bilateral elongation of
the Achilles tendon was performed.
Total urinary GAG excretion was only slightly above
the upper limit of normal for age during the last 6 years.
Urinary GAG electrophoresis showed the presence of
DS and CS with a ratio of about 50/50 already observed
Fig. 4 Timeline of follow up and the outcomes of the patients
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at the age of 11 years [5]. HS, present before ERT, disap-
peared after 5 months.
Plasma GAGs at the age of 5 years, before ERT, were
18.2 μg/ml (nv: 5.27 μg/ml ± 3.01) with a CS/DS ratio of
25/75 (nv: 100/0); after 6, 9 and 10 year of ERT, plasma
GAGs have remained within the normal range for age,
with only traces of DS (CS/DS ratio of 98/2). After
12 years of ERT circulating anti-laronidase antibodies
were not detectable.
The timeline of follow up and outcomes is reported in
Fig. 4.
Conclusions
Hundreds of MPS I patients have received ERT since the
approval of laronidase [6–8]; however, the vast majority
of them commence treatment when they have already a
considerable disease burden. Published long-term follow
up data show that although ERT is able to substantially
modify the natural history of disease, it does have limita-
tions in its ability to reverse key clinical manifestations
[9–12]. Recently, these results have been also confirmed
by Al-Sannaa N.A. et al. [13] on 4 patients treated dur-
ing the first year of life. In fact, ERT is able to reverse
some clinical signs such as thickness of the skin and
hepato-splenomegaly, but ERT has limitation in relation
to reversal of existing joint range of motion abnormal-
ities. In addition, ERT is less efficient in altering other
manifestations, once they are established, such as dysos-
tosis multiplex, cardiac valvulopathology, and corneal
clouding [7, 9], which result from a complex pathogenic
cascades leading to irreversible damage of the connective
tissue [11]. It appears that initiation of ERT when signifi-
cant arthropathy is present leads to some improvement
of joint range of motion in the first 1–2 years of treat-
ment, followed by disease stabilization or a slower rate
of disease progression. These observations have led to
the assumption that very early initiation of ERT i.e. prior
to significant manifestation of skeletal disease, may lead
to improved long-term outcomes for patients. Similar
arguments have been made in relation to the potential
impact of early initiation of ERT on other key clinical
signs such as cardiac, ophthalmologic and respiratory
manifestations. The comparative observations after
12 years of ERT in this unique sibling pair provide con-
vincing evidence of substantial differences in the impact
of ERT in MPS I when therapy is initiated prior to sig-
nificant disease manifestations. Notably, the skeletal,
joint and cardiac valve involvement has continued to
progress over eleven years of therapy in the sibling who
started therapy at the age 5 years whilst the younger sib-
ling, who started therapy at 5 months, shows minimal
joint and cardiac disease with no evidence of progression
of corneal disease. Despite the lack of symptoms related
to skeletal involvement in the sibling who commenced
therapy at a young age, he does indeed show evidence of
thoracic vertebral involvement as well as cardiac valvular
disease by the age of 7 years. Biochemical observations
of this sibling pair reveal that later in childhood, a mod-
erate increase of total urinary GAGs and more notably
dermatan sulphate was observed. Moreover, normal level
of plasmatic total GAGs were present, with only traces
of DS. No HS, present before ERT, was detected both in
urine and plasma. Recently, De Ru et al. [14] and
Langereis et al. [15] reported that the presence of DS
and HS could be related to the dose of ERT or to the
antibody status of the patients. On the basis of these
data and the clinical and biochemical results in our
patients, we hypothesized that the amount of enzyme
supplied could be one of the causes of the insufficient
GAG degradation. Therefore, the appearance of clinical
signs even after early therapy would indicate that either
increased ERT dosing or additional adjuvant therapeu-
tics should be considered. In fact, studies in MPS animal
models indicate that early alterations of the extracellular
matrix and inflammatory mechanisms likely play a role
in the progressive skeletal and connective tissue disease
[16, 17]. Therefore, the addition of adjuvant therapies
targeted to these pathways or therapies targeting
substrate reduction may be required in order to afford
the best outcome for patients.
This case report illustrates that early treatment sub-
stantially modifies the natural history of the attenuated
form of MPS I, and brings to the forefront the import-
ance and potential impact that neonatal screening and
early treatment initiation could have for this progressive
disease.
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